You are here
FDA Grants Orphan Drug Designation to Tocosol Paclitaxel in Bladder Cancer
In parallel with developing TOCOSOL Paclitaxel for the treatment of bladder cancer, Sonus is pursuing initial market entry through a 505(b)(2) New Drug Application in an indication for which paclitaxel-based products have already been approved, e.g. breast, ovarian or lung cancers. The Company is currently in discussions with the FDA to finalize the pivotal Phase 3 protocol for TOCOSOL Paclitaxel, which Sonus believes will be initiated in 2005.
"We have been pursuing the Phase 2b program since the end of 2003 to demonstrate the value of TOCOSOL Paclitaxel for treating bladder cancer," said Michael B. Stewart, M.D., Chief Medical Officer of Sonus Pharmaceuticals. "By granting both Orphan Drug and Fast Track status to TOCOSOL Paclitaxel, the FDA recognizes the potential of our drug to treat advanced cancers of the bladder and urinary system -- an uncommon, but important medical need. Currently available treatments are not particularly effective and/or have serious side effects. Despite the challenge of performing rigorously controlled clinical trials in a disease with a small patient population, we believe that addressing this need is an important component of the overall development objective for TOCOSOL Paclitaxel, and we are pleased that the FDA has agreed with us."
The Company is conducting Phase 2b bladder cancer studies in Cleveland, Philadelphia, Baltimore and Seattle, and will soon be opening sites in Spain and the U.K. In addition to the bladder cancer program, Sonus is also conducting a Phase 2b study of TOCOSOL Paclitaxel in patients with metastatic breast cancer.
Sonus has completed patient enrollment in Phase 2a studies of TOCOSOL Paclitaxel in bladder, ovarian and lung cancer patients, and these trials have generated encouraging data on safety and anti-tumor activity. The Company reported results of the Phase 2a studies in three presentations at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2004. TOCOSOL Paclitaxel offers the convenience of a ready-to-use formulation, which does not require reconstitution, dilution or pharmacy preparation as is required with the marketed paclitaxel products. Additionally, TOCOSOL Paclitaxel is administered to patients in a short 15-minute infusion, compared to the three-hour infusion required with Taxol(R), the innovator paclitaxel product.
About FDA Orphan Drug and Fast Track Designations
Products designated as orphan drugs are those that are being developed to treat diseases affecting fewer than 200,000 people in the United States. The Orphan Drug Act guarantees seven years of market exclusivity to the first sponsor that obtains market approval for an orphan-designated product. Additional incentives for the sponsor include tax credits related to clinical trial expenses and a waiver from the FDA user fee for review of an application for the indication designated.
The FDA's Fast Track program is intended to facilitate the development and review of new drugs intended to treat serious or life-threatening conditions, and for which the product has the potential to address an unmet medical need.
Source: Sonus Pharmaceuticals, Inc.